var title_f24_56_25472="Acetaminophen poisoning nomogram";
var content_f24_56_25472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Acetaminophen poisoning nomogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 590px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This nomogram should only be used after a single acute acetaminophen ingestion. The line indicates the level at which toxicity is possible after acetaminophen overdose. A serum acetaminophen level should be obtained four or more hours after an ingestion to ensure that a peak level has occurred. Patients who ingest extended-release preparations should have a second level drawn four hours after the first level to assess for an additional rise in serum concentration. The level should be plotted in relationship to the time of ingestion to determine the likelihood of toxicity and the need for treatment. Caution should be used in assessing the reliability of the time of ingestion. This nomogram cannot be used for ingestions that occurred greater than 24 hours prior to presentation, repeated supratherapeutic oral ingestions, or iatrogenic intravenous overdose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original nomogram from: Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55:871. Copyright &copy; 1975 by the AAP. Updated version reproduced with permission from: Dart RC, Rumack BH. Acetaminophen (Paracetamol). In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25472=[""].join("\n");
var outline_f24_56_25472=null;
var title_f24_56_25473="Treatment protocols for squamous cell carcinoma of the head and neck";
var content_f24_56_25473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for squamous cell carcinoma of the head and neck",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25473/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/56/25473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6926729\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with squamous cell carcinoma of the head and neck.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with squamous cell carcinoma of the head and neck. Additional regimens may be added over time, particularly as treatment for squamous cell carcinoma of the head and neck evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with squamous cell carcinoma of the head and neck. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120499976\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560463784\">",
"    <span class=\"h2\">",
"     Docetaxel, cisplatin, fluorouracil (TAX324)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65438 \" href=\"UTD.htm?41/48/42766\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560463797\">",
"    <span class=\"h2\">",
"     Docetaxel, cisplatin, fluorouracil (TAX323)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef72461 \" href=\"UTD.htm?40/58/41902\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937049771\">",
"    <span class=\"h2\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56253 \" href=\"UTD.htm?9/62/10221\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85694 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-4F267068D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25473=[""].join("\n");
var outline_f24_56_25473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6926729\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H120499976\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560463784\">",
"      Docetaxel, cisplatin, fluorouracil (TAX324)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560463797\">",
"      Docetaxel, cisplatin, fluorouracil (TAX323)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H937049771\">",
"      Cetuximab",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42766\" title=\"table 1\">",
"      Docetaxel cisplatin and FU plus chemoRT HNC ver1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/58/41902\" title=\"table 2\">",
"      Docetaxel cisplatin and FU plus RT HNC ver2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/62/10221\" title=\"table 3\">",
"      Cetuximab for recurrent and-or metastatic head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25474="Autoimmune hepatitis";
var content_f24_56_25474=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Autoimmune hepatitis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/56/25474/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25474/contributors\" id=\"au8657\">",
"       Michael A Heneghan, MD, MMedSc, FRCPI",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/56/25474/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25474/contributors\" id=\"se6409\">",
"       Sanjiv Chopra, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/56/25474/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25474/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/56/25474?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      AUTOIMMUNE HEPATITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The liver is one of the largest and most important organs in the body. It functions to cleanse toxins from the blood, break down medications, and aids in digestion and blood clotting.",
"    </p>",
"    <p>",
"     Hepatitis is a general term that means inflammation of the liver. There are many forms and causes of hepatitis (such as viruses and certain drugs), including autoimmune hepatitis. In autoimmune hepatitis, the body's immune system attacks the cells of the liver, which causes the liver to become inflamed.",
"    </p>",
"    <p>",
"     Topics that discuss other types of hepatitis are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      \"Patient information: Hepatitis A (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      \"Patient information: Hepatitis B (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      \"Patient information: Hepatitis C (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AUTOIMMUNE HEPATITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     It is not clear why autoimmune hepatitis develops. Researchers suspect that some people inherit a genetic disposition that could make them more likely to develop it. Sometimes drugs or infections trigger the development of the disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPES OF AUTOIMMUNE HEPATITIS",
"     </span>",
"    </p>",
"    <p>",
"     There are two major forms of autoimmune hepatitis: type 1 and type 2.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Type 1 autoimmune hepatitis can affect people of any age or gender",
"      </li>",
"      <li>",
"       Type 2 autoimmune hepatitis primarily affects girls and young women and is less common",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There are also rare forms of autoimmune hepatitis (called variants) that have features of both autoimmune hepatitis and other liver diseases (primary sclerosing cholangitis or primary biliary cirrhosis).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      AUTOIMMUNE HEPATITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Many patients with autoimmune hepatitis have no symptoms. The disorder is often first detected by abnormal laboratory tests performed for an unrelated reason (such as for a life insurance examination).",
"    </p>",
"    <p>",
"     When symptoms are present, the most common symptom is fatigue. Some people also have additional symptoms, including jaundice (yellowing of the skin or eyes), itching, skin rashes, joint pain, abdominal discomfort, nausea, vomiting, loss of appetite, dark urine, and pale or gray-colored stools. In its most advanced form, autoimmune hepatitis can progress to cirrhosis (severe scarring of the liver). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      AUTOIMMUNE HEPATITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Autoimmune hepatitis is diagnosed with blood tests and a liver biopsy. During a liver biopsy, a small sample of liver tissue is removed for examination under a microscope. The biopsy can help to confirm the diagnosis and determine its severity while excluding other l causes of liver disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=see_link\">",
"      \"Patient information: Liver biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      AUTOIMMUNE HEPATITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Not everyone with autoimmune hepatitis needs treatment immediately. The decision to treat is based upon the severity of symptoms, the severity of the disease (based upon results of blood tests and the liver biopsy), and the potential side effects of treatment. The guidelines for treatment can be found online at the American Association for the Study of Liver Diseases (",
"     <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"      file://www.aasld.org/practiceguidelines/Pages/default.aspx",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Autoimmune hepatitis is usually treated first with a glucocorticoid (such as prednisone).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Glucocorticoids &ndash; Glucocorticoids such as prednisone control the inflammation in the liver, thereby preventing further scarring. The main drawback of prednisone is side effects, which can include weight gain, acne, bone loss, elevated blood glucose levels (potentially leading to diabetes), an increased risk of infections, cataracts, high blood pressure, and mood and sleep disturbance, among others. People who require long-term prednisone are monitored carefully for these side effects. To minimize the risks of side effects, the lowest possible dose of prednisone is used.",
"      </li>",
"      <li>",
"       Azathioprine or 6-mercaptopurine &ndash; A second medication, such as azathioprine {Azasan&reg;; Imuran&reg;} or 6-mercaptopurine (Purinethol&reg;) and, less commonly, methotrexate or mycophenolate mofetil, may be recommended in addition to prednisone. The benefit of adding a second medication is that it may be possible to reduce or eliminate prednisone, helping to minimize the potential side effects of prednisone.",
"      </li>",
"      <li>",
"       Budesonide &ndash; Budesonide, another medication that may be substituted for prednisone, continues to be studied, but is not yet widely used.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Azathioprine and 6-mercaptopurine can also cause side effects, including allergic reactions, a low white blood cell count, inflammation of the pancreas, nausea, and abnormal liver blood tests (which can sometimes cause confusion as to whether the abnormal results are from the autoimmune hepatitis or the drugs used to treat it). There may be a small increased risk of certain types of cancer (such as lymphoma). Blood tests to monitor for these conditions are performed regularly while taking these medications.",
"    </p>",
"    <p>",
"     Mycophenolate has several potential risks, including an increased risk of developing infections or cancers (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/druginfo/meds/a601081.html\">",
"      www.nlm.nih.gov/medlineplus/druginfo/meds/a601081.html",
"     </a>",
"     ). Mycophenolate can cause birth defects and should not be taken during pregnancy. Men and women who use mycophenolate must use two effective methods to prevent pregnancy (eg, condoms and a birth control pill).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Duration of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;As a general rule, treatment is continued until the disease is in remission, the treatment fails, or the person develops severe side effects from treatment.",
"    </p>",
"    <p>",
"     Remission is defined as a lack of symptoms, normal or near normal levels of liver blood tests, and improvement in the appearance of liver tissue (based upon a biopsy). The initial period of remission generally occurs 12 or more months after treatment begins. Approximately 65 and 80 percent of patients achieve remission by 18 months and three years, respectively.",
"    </p>",
"    <p>",
"     Approximately 50 percent of patients remain in remission or have only mild disease activity for months to years after treatment is stopped [",
"     <a class=\"abstract\" href=\"UTD.htm?24/56/25474/abstract/1\">",
"      1",
"     </a>",
"     ]. However, most patients must eventually restart treatment because the disease becomes active again (relapse). Relapse typically occurs within the first 15 to 20 months after treatment is stopped. Relapse is more likely in those who have cirrhosis on the initial liver biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      If medications are not used",
"     </span>",
"     &nbsp;&mdash;&nbsp;Close follow-up is recommended for people who are not initially treated with medications. Follow-up generally includes a physical examination and blood tests every few months, and a liver biopsy is usually repeated at least every two years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Self care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Taking medication and seeing a healthcare provider on a regular basis can help to ensure that the liver remains as healthy as possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;No specific diet has been shown to improve the outcome in patients with autoimmune hepatitis. The best advice is to eat a normal, healthy and balanced diet and to avoid becoming obese; obesity can increase the risk of fatty liver disease and may complicate autoimmune hepatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol should be avoided since it can cause fatty liver and other liver damage. All types of alcoholic beverages can be harmful to the liver, including beer, wine, and liquor. Patients with liver disease may worsen with even small amounts of alcohol.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise is good for overall health and is encouraged, but it has no specific benefit for people with autoimmune hepatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Prescription and nonprescription drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many drugs are broken down by the liver. Thus, it is always best to check with a healthcare provider or pharmacist before starting a new prescription. Unless the liver is already scarred, most drugs are safe. Some people with active liver disease will be advised to take a smaller dose of medication.",
"    </p>",
"    <p>",
"     An important exception is acetaminophen (Tylenol), commonly used for headaches, other aches and pains, and fever. In people with any type of liver disease, the maximum recommended dose of acetaminophen is no more than 2000 mg (in divided doses) per 24 hours. Thus, it is reasonable to take 500 mg every four to six hours, although this should not be repeated more than four times in one day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Herbal medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of claims, particularly on the internet, that herbal medications can improve liver health. However, no single or combination of herbs has been proven to improve outcomes in patients with autoimmune hepatitis. Some herbs can cause serious liver damage, and some have been implicated in triggering autoimmune hepatitis. For this reason, we do not currently recommend any herbal treatment for liver disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;Do not underestimate the value of sharing your concerns with other people with autoimmune hepatitis. Ask your healthcare provider about support groups or other patients who may be willing to discuss their experiences with autoimmune hepatitis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PREGNANCY AND AUTOIMMUNE HEPATITIS",
"     </span>",
"    </p>",
"    <p>",
"     Women who are treated for autoimmune hepatitis can have successful pregnancies. Treatment usually includes glucocorticoids",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     azathioprine, both of which are probably safe during pregnancy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     .) Stopping treatment during pregnancy can lead to relapse of the disease, and is not usually recommended.",
"    </p>",
"    <p>",
"     However, babies of women with autoimmune hepatitis may have an increased risk of prematurity, low birth weight, and other fetal problems. Women need to be monitored carefully during pregnancy and several months after delivery because of the risk of flares in disease activity.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      LONG-TERM OUTCOME",
"     </span>",
"    </p>",
"    <p>",
"     Untreated autoimmune hepatitis can cause scarring of the liver and ultimately lead to cirrhosis and liver failure. Fortunately, proper treatment can prevent scarring and cirrhosis in most patients. Treatment can be beneficial, even if advanced scarring or cirrhosis has already developed, arresting progression of scarring and, sometimes, reversing the scarring.",
"    </p>",
"    <p>",
"     Approximately 10 to 40 percent of people with autoimmune hepatitis go into remission and no longer need medications for their condition; however, only about 50 percent of these people stay in remission. Thus, most patients need either continuous therapy or additional rounds of medication to treat ongoing disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21384512\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21384481\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21384489\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498736498\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=see_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information:",
"     </span>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27140?source=see_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=see_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31812?source=see_link\">",
"      Extrahepatic manifestations of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=see_link\">",
"      Pathogenesis of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42902?source=see_link\">",
"      Serologic markers of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association for the Study of Liver Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aasld.org/\">",
"      www.aasld.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Liver Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"      www.liverfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hepatitis Foundation International",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hepfi.org/\">",
"      www.hepfi.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institutes of Health: Clinical Trials",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"      www.clinicaltrials.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/56/25474/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/56/25474?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/1\">",
"      Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/2\">",
"      Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2004; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/3\">",
"      Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/4\">",
"      Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/5\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/6\">",
"      Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25474/abstract/7\">",
"      Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_56_25474=[""].join("\n");
var outline_f24_56_25474=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           AUTOIMMUNE HEPATITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AUTOIMMUNE HEPATITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPES OF AUTOIMMUNE HEPATITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           AUTOIMMUNE HEPATITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           AUTOIMMUNE HEPATITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           AUTOIMMUNE HEPATITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PREGNANCY AND AUTOIMMUNE HEPATITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           LONG-TERM OUTCOME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25475="Maffucci syndrome";
var content_f24_56_25475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Maffucci syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Plain radiograph demonstrates multiple soft-tissue masses and calcified thrombi in association with expansile bony lesions.",
"    <br>",
"     B) Late film from an arteriogram shows contrast material filling many cavernous hemangiomas of the soft tissues.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25475=[""].join("\n");
var outline_f24_56_25475=null;
var title_f24_56_25476="Bethanechol: Drug information";
var content_f24_56_25476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bethanechol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/14/15588?source=see_link\">",
"    see \"Bethanechol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/58/16291?source=see_link\">",
"    see \"Bethanechol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Urecholine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duvoid&reg;;",
"     </li>",
"     <li>",
"      PHL-Bethanechol;",
"     </li>",
"     <li>",
"      PMS-Bethanechol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Cholinergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary retention, neurogenic bladder:",
"     </b>",
"     Oral: Initial: 10-50 mg 3-4 times/day (some patients may require dosages of 50-100 mg 4 times/day). To determine effective dose, may initiate at a dose of 5-10 mg, with additional doses of 5-10 mg hourly until an effective cumulative dose is reached. Cholinergic effects at higher oral dosages may be cumulative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastroesophageal reflux (unlabeled):",
"     </b>",
"     Oral: 25 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/58/16291?source=see_link\">",
"      see \"Bethanechol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary retention (unlabeled use):",
"     </b>",
"     Oral: 0.3-0.6 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastroesophageal reflux (unlabeled use):",
"     </b>",
"     Oral: 0.3-0.6 mg/kg/day in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use the lowest effective dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chloride: 5 mg, 10 mg, 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urecholine&reg;: 5 mg, 10 mg, 25 mg, 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8120617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duvoid&reg;: 10 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered 1 hour before meals or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention; treatment of neurogenic atony of the urinary bladder with retention",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F140955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastroesophageal reflux",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bethanechol may be confused with betaxolol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, tachycardia, flushed skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, belching, borborygmi, colicky pain, diarrhea, nausea, vomiting, salivation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthmatic attacks, bronchial constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bethanechol or any component of the formulation; mechanical obstruction of the GI or GU tract or when the strength or integrity of the GI or bladder wall is in question; hyperthyroidism, peptic ulcer disease, epilepsy, asthma, bradycardia, vasomotor instability, coronary artery disease, hypotension, or parkinsonism",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reflux infection: Potential for reflux infection if the sphincter fails to relax as bethanechol contracts the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5540284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5357780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F140939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16248958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bethanechol is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F140923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1 hour before meals or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bethanechol Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $71.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $133.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $178.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $285.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Urecholine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $182.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $297.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $455.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $634.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F140913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe closely for side effects.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dampurine (TW);",
"     </li>",
"     <li>",
"      Hinecol (KP);",
"     </li>",
"     <li>",
"      Liberon (BR);",
"     </li>",
"     <li>",
"      Miotonoachol (AR);",
"     </li>",
"     <li>",
"      Muscaran (BE, LU);",
"     </li>",
"     <li>",
"      Myo Hermes (ES);",
"     </li>",
"     <li>",
"      Myocholine Glenwood (CH);",
"     </li>",
"     <li>",
"      Myocholine-Glenwood (AT, DE, IT);",
"     </li>",
"     <li>",
"      Myotonin (KP);",
"     </li>",
"     <li>",
"      Myotonine Chloride (GB, UY);",
"     </li>",
"     <li>",
"      Ucholine (TH);",
"     </li>",
"     <li>",
"      Uninechol (KP);",
"     </li>",
"     <li>",
"      Urecholine (FI);",
"     </li>",
"     <li>",
"      Uriflow (PH);",
"     </li>",
"     <li>",
"      Urocarb (AU);",
"     </li>",
"     <li>",
"      Urotone (IN);",
"     </li>",
"     <li>",
"      Wecoli (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to stimulation of the parasympathetic nervous system, bethanechol increases bladder muscle tone causing contractions which initiate urination. Bethanechol also stimulates gastric motility, increases gastric tone and may restore peristalsis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andersson KE, &ldquo;Current Concepts in the Treatment of Disorders of Micturition,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1988, 35(4):477-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/3292211/pubmed\" id=\"3292211\" target=\"_blank\">",
"        3292211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borzyskowski M and Mundy AR, &ldquo;The Management of the Neuropathic Bladder in Childhood,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 1988, 2(1):56-66",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/2908664/pubmed\" id=\"2908664\" target=\"_blank\">",
"        2908664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farrell RL, Roling GT, and Castell DO, &ldquo;Cholinergic Therapy of Chronic Heartburn. A Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1974, 80(5):573-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/4596046/pubmed\" id=\"4596046\" target=\"_blank\">",
"        4596046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holloway RH,  McCallum RW. &ldquo;A Practical Approach to Gastroesophageal Reflux,&rdquo;",
"      <i>",
"       Drug Ther",
"      </i>",
"      , 1983, 13(3):151-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guerra MF and Ives TJ, &ldquo;Bethanechol and Hypothermia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1983, 99(2):279-80.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romanowski GL, Shimp LA, Balson AB, et al, &ldquo;Urinary Incontinence in the Elderly: Etiology and Treatment,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1988, 22(7-8):525-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/3046886/pubmed\" id=\"3046886\" target=\"_blank\">",
"        3046886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sher PP, &ldquo;Drug Interferences With Clinical Laboratory Tests,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1982, 24(1):24-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/6179732/pubmed\" id=\"6179732\" target=\"_blank\">",
"        6179732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sondheimer JM, Mintz, HL, and Michaels M. &ldquo;Bethanechol Treatment of Gastroesophageal Reflux in Infants: Effect on Continuous Esophageal pH Records.,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1984, 104(1):128-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25476/abstract-text/6690657/pubmed\" id=\"6690657\" target=\"_blank\">",
"        6690657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9153 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-E5FD8A8851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25476=[""].join("\n");
var outline_f24_56_25476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140932\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140933\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140958\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140936\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140947\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140937\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682291\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682292\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140915\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120617\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140899\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460144\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140917\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140955\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140965\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140956\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140903\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298859\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5540284\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357780\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140939\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248958\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140923\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140922\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140913\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038540\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140902\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140919\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/14/15588?source=related_link\">",
"      Bethanechol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/58/16291?source=related_link\">",
"      Bethanechol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25477="Trichiasis in ocular cicatricial pemphigoid";
var content_f24_56_25477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Trichiasis in ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distortion of the adnexal relationships and trichiasis (eyelashes turning in to touch the cornea) are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25477=[""].join("\n");
var outline_f24_56_25477=null;
var title_f24_56_25478="Babesia microti thin smear";
var content_f24_56_25478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Babesia microti parasites in red blood cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Panel A)",
"    </strong>",
"    Babesia microti",
"    <sup>",
"     [1]",
"    </sup>",
"    . This thin peripheral blood smear (Giemsa stain; x1000) shows Babesia microti. Several erythrocytes contain multiple parasites, including a diagnostic tetrad form (arrow).",
"    <strong>",
"     Panel B)",
"    </strong>",
"    Malaria (for comparison)",
"    <sup>",
"     [2]",
"    </sup>",
"    . Peripheral smear from a patient with malaria shows intraerythrocytic ring forms (trophozoites) (arrows).",
"    <strong>",
"     Panel C)",
"    </strong>",
"    Normal",
"    <sup>",
"     [2]",
"    </sup>",
"    . High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of:",
"     <br>",
"      1. Harriet Provine",
"      <br>",
"       2. Carola von Kapff, SH (ASCP).",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25478=[""].join("\n");
var outline_f24_56_25478=null;
var title_f24_56_25479="Pioglitazone and metformin: Drug information";
var content_f24_56_25479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pioglitazone and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/19/19766?source=see_link\">",
"    see \"Pioglitazone and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1615054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actoplus Met&reg;;",
"     </li>",
"     <li>",
"      Actoplus Met&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1615058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Thiazolidinedione",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1615087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral: Initial dose should be based on current dose of pioglitazone and/or metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: Pioglitazone 15 mg plus metformin 500 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     pioglitazone 15 mg plus metformin 850 mg tablets once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients with heart failure (NYHA Class I or II): Initial: Pioglitazone 15 mg plus metformin 500 mg once daily",
"     <b>",
"      or",
"     </b>",
"     pioglitazone 15 mg plus metformin 850 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended in patients with symptomatic heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose titration: If necessary, may titrate gradually with careful monitoring of adverse effects (eg, weight gain, edema, signs/symptoms of heart failure). Maximum daily dose: Pioglitazone 45 mg/metformin 2550 mg.",
"     <b>",
"      Note:",
"     </b>",
"     Metformin daily doses &gt;2000 mg may be better tolerated if given 3 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Variable release tablet:",
"     </i>",
"     Initial: Pioglitazone 15-30 mg plus metformin 1000 mg once daily with evening meal. If necessary, titrate gradually with careful monitoring of adverse effects (eg, weight gain, edema, signs/symptoms of heart failure). Maximum daily dose: Pioglitazone 45 mg/metformin 2000 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for hypoglycemia with combination therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      With an insulin secretagogue (eg, sulfonylurea):",
"     </i>",
"     Decrease the insulin secretagogue dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      With insulin:",
"     </i>",
"     Decrease insulin dose by 10% to 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment with strong CYP2C8 inhibitors (eg, gemfibrozil):",
"     </b>",
"     Maximum recommended dose: Pioglitazone 15 mg plus metformin 850 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1615088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Immediate release or variable release tablet:",
"     </i>",
"     Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor). Generally, elderly patients should not be titrated to the maximum; do not use in patients &ge;80 years of age unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1615089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Immediate release or variable release tablet:",
"     </i>",
"     Contraindicated in patients with renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or  &ge;1.4 mg/dL in females or abnormal clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1615090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Immediate release or variable release:",
"     </i>",
"     Not recommended in hepatic impairment due to potential for lactic acidosis associated with metformin component.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1615096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 15/500: Pioglitazone 15 mg and metformin hydrochloride 500 mg; 15/850: Pioglitazone 15 mg and metformin hydrochloride 850 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Actoplus Met&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     15/500: Pioglitazone 15 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     15/850: Pioglitazone 15 mg and metformin hydrochloride 850 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Actoplus Met&reg; XR:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     15/1000: Pioglitazone 15 mg [immediate release] and metformin hydrochloride 1000 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30/1000: Pioglitazone 30 mg [immediate release] and metformin hydrochloride 1000 mg [extended release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1615056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes variable release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9350997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Actoplus Met&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188473.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188473.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Actoplus Met&reg; XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170914.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170914.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1615092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulation: Administer with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Variable release formulation: Administer with the evening meal. Tablets should be swallowed whole; do not crush, split, or chew. Inactive tablet ingredients may be eliminated in the feces as a soft mass that resembles the original tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1615060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) in patients already receiving a thiazolidinedione and metformin or who have inadequate control on either agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14198938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1615072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents. Percentages of adverse effects as reported with the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (lower limb, 3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (12% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2% to 6%), dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Weight gain (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (5% to 6%), nausea (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (4% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1615067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pioglitazone, metformin, or any component of the formulation; NYHA Class III/IV heart failure (initiation of therapy); renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females, or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia); acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis); concurrent iodinated radiocontrast administration (manufacturer recommends temporary discontinuation of metformin)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1615068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder cancer: Clinical trial data suggest an increased risk of bladder cancer in patients exposed to pioglitazone; risk may be increased with duration of use. Avoid use in patients with active bladder cancer and consider risks vs. benefits prior to initiating therapy in patients with a history of bladder cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Dose-related edema, including new-onset or exacerbation of existing edema, has been reported with pioglitazone; use with caution in patients with edema. Monitor for signs/symptoms of heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of bone fractures in females treated with pioglitazone;  majority of fractures occurred in the lower limb and  distal upper limb. Consider risk of fracture prior to initiation and during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure/cardiac effects:",
"     <b>",
"      [U.S. Boxed Warning]: Thiazolidinediones, including pioglitazone, may cause or exacerbate heart failure; closely monitor for signs and symptoms of heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases; if heart failure develops, treat accordingly and consider dose reduction or discontinuation. Not recommended for use in any patient with symptomatic heart failure; initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure.",
"     </b>",
"     If used in patients with NYHA class I or II (systolic) heart failure, initiate at lowest dosage and monitor closely. In addition, metformin should be used with caution in patients with heart failure requiring pharmacologic management, particularly in unstable or acute heart failure due to risk of lactic acidosis secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Pioglitazone may decrease hemoglobin/hematocrit; effects may be related to increased plasma volume. Metformin may impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption; monitor for anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic failure, including fatalities, has been reported with pioglitazone. Monitor for signs/symptoms of liver injury closely during therapy; discontinuation of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The risk of hypoglycemia is increased when pioglitazone is combined with insulin or other diabetic medications; dosage adjustment of concomitant hypoglycemic agents may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy and all diabetic patients should have regular eye exams.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Dose-related weight gain observed with pioglitazone use; mechanism unknown but likely associated with fluid retention and fat accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use pioglitazone with caution in patients with anemia; may reduce hemoglobin and hematocrit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes, type 1: Mechanism of pioglitazone requires the presence of insulin; therefore, use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis. Due to the possible risk of drug-induced liver injury with pioglitazone use, serum liver tests (ALT, AST, alkaline phosphatase, and total bilirubin) should be obtained prior to initiation in all patients. In patients with abnormal hepatic tests, therapy should be initiated with caution.  During therapy, if signs/symptoms of liver injury (eg, fatigue, anorexia, jaundice, dark urine, right upper abdominal discomfort) arise, interrupt therapy, obtain liver tests immediately, and evaluate alternative etiologies. Routine periodic monitoring of serum liver tests during therapy is not necessary unless patient has liver disease or signs/symptoms of liver injury arise during use. Idiosyncratic hepatotoxicity has been reported with another thiazolidinedione agent (troglitazone); avoid use in patients who previously experienced jaundice during troglitazone therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2C8 inhibitors: Concomitant administration of pioglitazone with a strong CYP2C8 inhibitor increases pioglitazone exposure 3-fold; dosage adjustments are recommended if coadministered with a strong CYP2C8 inhibitor (eg, gemfibrozil).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal/anovulatory females: Use pioglitazone with caution in premenopausal, anovulatory women; may result in a resumption of ovulation, increasing the risk of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Metformin therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1615078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1615077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione). Management: Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregabalin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1615080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1615062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1615063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted with this combination; therefore, pioglitazone/metformin is classified as pregnancy category C. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1615065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1615066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1615091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate release tablets should be administered with meals. Variable release tablets should be administered with the evening meal. Avoid ethanol. Dietary modification based on ADA recommendations is a part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Actoplus met XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-1000 mg (30): $211.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-1000 mg (30): $418.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Actoplus Met Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-500 mg (60): $390.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-850 mg (60): $390.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pioglitazone HCl-Metformin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-500 mg (60): $319.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-850 mg (60): $319.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1615094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , serum glucose; signs and symptoms of heart failure; liver enzymes (ALT, AST, alkaline phosphatase, and total bilirubin) prior to initiation in all patients and during treatment if signs/symptoms of liver dysfunction arise.  Initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices) and renal function should performed. Check vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate if anemia is present. Routine ophthalmic exams recommended; patients reporting visual deterioration should have a prompt referral to an ophthalmologist and consideration should be given to discontinuing pioglitazone. Signs/symptoms of bladder cancer (dysuria, macroscopic hematuria, dysuria, urinary urgency).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6117925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actos M (AR);",
"     </li>",
"     <li>",
"      Actos Met (CN, EC, PE);",
"     </li>",
"     <li>",
"      Actosmet (HK, KP, PH, TH, TW);",
"     </li>",
"     <li>",
"      Cereluc Met (AR);",
"     </li>",
"     <li>",
"      Competact (AT, CH, CZ, DE, EE, FR, GB, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Diavista-M (IN);",
"     </li>",
"     <li>",
"      Furuitong (CL);",
"     </li>",
"     <li>",
"      Nilgar M-15 (PH);",
"     </li>",
"     <li>",
"      Nilgar M-30 (PH);",
"     </li>",
"     <li>",
"      Pioglit-MF15 (IN);",
"     </li>",
"     <li>",
"      Pionix-M (ID);",
"     </li>",
"     <li>",
"      Prialta-Met (PH);",
"     </li>",
"     <li>",
"      Zolid Plus (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1615083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1615084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lago RM, Singh PP, and Nesto RW, &ldquo;Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370 (9593):1129-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/17905165/pubmed\" id=\"17905165\" target=\"_blank\">",
"        17905165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Wolski K, Nicholls SJ, et al, &ldquo;Pioglitazone an Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(10):1180-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/17848652/pubmed\" id=\"17848652\" target=\"_blank\">",
"        17848652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simpson SH, Majumdar SR, Tsuyuki RT, et al, &ldquo;Dose-Response Relation between Sulfonylurea Drugs and Mortalility in Type 2 Diabetes Mellitus: A Population-Based Cohort Study,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2006, 174(2):169-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/16415461/pubmed\" id=\"16415461\" target=\"_blank\">",
"        16415461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, &ldquo;Thiazolidinedione Use and Bone Loss in Older Diabetic Adults,&rdquo;",
"      <i>",
"       J Clin Endocrin Metab",
"      </i>",
"      , 2006, 91(9):3349-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/16608888/pubmed\" id=\"16608888\" target=\"_blank\">",
"        16608888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      University Group Diabetes Program, &ldquo;A Study of the Effects of Hypoglycemia Agents of Vascular Complications in Patients with Adult-Onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated with Tolbutamide,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaturu S, Bryant B, Jain SK, &ldquo;Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(6):1574-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25479/abstract-text/17363747/pubmed\" id=\"17363747\" target=\"_blank\">",
"        17363747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9472 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25479=[""].join("\n");
var outline_f24_56_25479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709214\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615054\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615058\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615087\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615088\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615089\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615090\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615096\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615056\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9350997\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615092\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615060\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198938\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615072\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615067\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615068\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615078\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615077\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615080\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615062\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615063\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615065\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615066\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615091\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422160\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615094\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6117925\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539960\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615083\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615084\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/19/19766?source=related_link\">",
"      Pioglitazone and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25480="RPGN EM";
var content_f24_56_25480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph in crescentic glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in RPGN showing characteristic breaks in the glomerular basement membrane (GBM) (arrows). These rents allow fibrin and cellular elements to enter Bowman's space and initiate crescent formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25480=[""].join("\n");
var outline_f24_56_25480=null;
var title_f24_56_25481="Escitalopram: Drug information";
var content_f24_56_25481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Escitalopram: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/1/44053?source=see_link\">",
"    see \"Escitalopram: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/21/36184?source=see_link\">",
"    see \"Escitalopram: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13502640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Canadian Product Labeling Updated in Regards to Risk of Cardiac Arrhythmias",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Heath Canada is notifying the Canadian public that escitalopram (Canadian brand name Cipralex&reg;) product monograph has been updated with warnings regarding dose-related risks for QT interval prolongation. The updated product monograph contraindicates use in patients with known QT interval prolongation or congenital long QT syndrome and recommends avoiding concomitant use of agents known to prolong the QT interval or reduce electrolyte concentrations. The maximum recommended dose of escitalopram is 20 mg/day for most patients, however a maximum of 10 mg/day is recommended for patients &gt;65 years of age, with hepatic dysfunction, or taking omeprazole or cimetidine.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Patients and their healthcare providers should discuss potential concerns (eg, existing heart disease, concomitant medications, low potassium or other electrolyte concentrations, or a strict diet) prior to initiating therapy. Patients are also advised to consult their healthcare provider when considering escitalopram dose reductions/discontinuation and to immediately report symptoms such as palpitations, fainting, dizziness, or seizures during therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at file://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_63-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F608961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cipralex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Major depressive disorder, generalized anxiety disorder:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Oral: Initial: 10 mg once daily; dose may be increased to a maximum of 20 mg once daily after at least 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Major depressive disorder, generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD):",
"     </b>",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Oral: Initial: 10 mg once daily (may consider 5 mg once daily where sensitivity is a concern); dose may be increased as tolerated to a maximum of 20 mg once daily. Patients with GAD or OCD who require extended therapy should be maintained at the lowest effective dose and assessed periodically to determine the need for continued therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Initiate treatment in poor CYP2C19 metabolizers at a dose of 5 mg once daily; may increase dose to a maximum of 10 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vasomotor symptoms associated with menopause (unlabeled use):",
"     </b>",
"     Initial: 10 mg once daily, increase to 20 mg once daily after 4 weeks if symptoms not adequately controlled  (Carpenter, 2012; Freeman, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of escitalopram.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing escitalopram and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate escitalopram in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving escitalopram and potential benefits outweigh potential risks, discontinue escitalopram promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume escitalopram 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant medications:",
"     </b>",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Escitalopram dose should not exceed 10 mg once daily in patients taking omeprazole or cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7689783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/21/36184?source=see_link\">",
"      see \"Escitalopram: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Major depressive disorder",
"     </b>",
"     Oral: Children &ge;12 years: Initial: 10 mg once daily; dose may be increased to a maximum of 20 mg once daily after at least 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Major depressive disorder, generalized anxiety disorder:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Major depressive disorder, generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD):",
"     </b>",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Oral: Initial: 5 mg once daily; dose may be increased as tolerated to a maximum of 10 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F166818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute (U.S. labeling) or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (Canadian labeling): Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F166819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild or moderate impairment (Child-Pugh class A or B): Initial: 5 mg once daily; dose may be increased as tolerated to 10 mg once daily (maximum dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe Impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mg/mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 1 mg/mL (240 mL) [contains propylene glycol; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexapro&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6813990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipralex&reg;: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088620.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088620.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily (morning or evening), with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder; generalized anxiety disorders (GAD)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Treatment of obsessive-compulsive disorder (OCD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5685303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild dementia-associated agitation in nonpsychotic patients; treatment of vasomotor symptoms associated with menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lexapro&reg; may be confused with Loxitane&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zavesca: Brand name for escitalopram [in multiple international markets; ISMP April 21, 2010], but also brand name for miglustat [Canada, U.S., and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (24%), somnolence (4% to 13%), insomnia (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6% to 14%), nausea (15% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculation disorder (9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (2% to 8%), dizziness (4% to 7%), abnormal dreaming (3%), lethargy (3%), yawning (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (3% to 7%), anorgasmia (2% to 6%), menstrual disorder (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4% to 9%), constipation (3% to 6%), indigestion (2% to 6%), appetite decreased (3%), vomiting (3%), abdominal pain (2%), flatulence (2%), toothache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (2% to 3%), urinary tract infection (children &ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck/shoulder pain (3%), back pain (children &ge;2%), paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (5%), sinusitis (3%), nasal congestion (children &ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (3% to 8%), flu-like syndrome (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal cramps, acute renal failure, aggression, agitation, agranulocytosis, akathisia, allergic reaction, allergy, alopecia, amnesia, anaphylaxis, anemia, angioedema, anxiety, apathy, aplastic anemia, appetite increased, arthralgia, ataxia, atrial fibrillation, bilirubin increased, blurred vision, bradycardia, bronchitis, cardiac failure, cerebrovascular accident, chest pain, choreoathetosis, concentration impaired delirium, delusion, depersonalization, depression aggravated, dermatitis, diabetes mellitus, diplopia, DVT, dyskinesia, dysphagia, dyspnea, dystonia, dysuria, ecchymosis, edema, epistaxis, erythema multiforme, extrapyramidal symptoms, fever, flushing, gait abnormal, gastroenteritis, GERD, GI hemorrhage, glaucoma, hallucination, heartburn, hemolytic anemia, hepatic necrosis, hepatitis, hot flashes, hypercholesterolemia, hyper-/hypoglycemia, hypertensive crisis, hypertension, hypoesthesia, hypokalemia, hyponatremia, hypotension, INR increased, irritability, jaw stiffness, leukopenia, lightheadedness, limb pain, liver enzymes increased, liver failure, menorrhagia, menstrual cramps, migraine, muscle weakness, myalgia, mydriasis, myocardial infarction, myoclonus, nasal congestion, neuroleptic malignant syndrome, nightmares, nystagmus, orthostasis, palpitation, pancreatitis, panic reaction, paranoia, Parkinsonism, phlebitis, photosensitivity, priapism, prolactinemia, prothrombin decreased, psychosis, pulmonary embolism, QT prolonged, rash, rectal hemorrhage, rhabdomyolysis, seizures, serotonin syndrome, SIADH, sinus congestion, sinus headache, spontaneous abortion, Stevens-Johnson syndrome, suicidal tendency, suicide attempt, syncope, tachycardia, tardive dyskinesia, thrombocytopenia, thrombocytopenic purpura (idiopathic), thrombosis, tinnitus, torsade de pointes, toxic epidermal necrolysis, tremor, urinary frequency, urinary retention, urticaria, ventricular arrhythmia, ventricular tachycardia, vertigo, visual disturbance, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to escitalopram, citalopram, or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either escitalopram or the MAO inhibitor); initiation of escitalopram in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Known QT-interval prolongation or congenital long QT syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Escitalopram is not FDA approved for use in children &lt;12 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: Use with caution in patients who are hemodynamically unstable. May impair platelet aggregation resulting in increased risk of bleeding events (including GI bleeding), particularly if used concomitantly with aspirin, NSAIDs, warfarin, or other anticoagulants. Bleeding related to SSRI or SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Use has been associated with dose-dependent QT interval prolongation with doses of 10 mg and 30 mg/day in healthy subjects (mean change from baseline: 4.3 msec and 10.7 msec, respectively); prolongation of  QT interval and ventricular arrhythmia (including torsade de pointes) have been reported, particularly in females with preexisting QT prolongation or other risk factors (eg, hypokalemia, other cardiac disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Hyponatremia is reversible with discontinuation of treatment. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Patients with a recent history of MI or unstable heart disease were excluded from clinical trials; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Escitalopram is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic disease: Use with caution; limited data in patients with altered metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). Bioavailability and half-life are increased by 50% in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy (ECT): Use with caution; no clinical studies have assessed the combined use of escitalopram and electroconvulsive therapy; may increase the risks (eg, cognitive adverse effects) associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of escitalopram therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Escitalopram. Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid the risk of escitalopram toxicity. Escitalopram Canadian product labeling recommends limiting escitalopram dose to 10 mg/day with concomitant use of cimetidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of Escitalopram. Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Escitalopram dosing recommendations may differ between international labelings in regards to concomitant use of omeprazole. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F166809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava, and gotu kola (may increase CNS depression and/or increase risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Escitalopram crosses the placenta and is distributed into the amniotic fluid. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of escitalopram or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known. Escitalopram is the S-enantiomer of the racemic derivative citalopram; also refer to the Citalopram monograph.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of escitalopram may be altered. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/consider risk:benefit",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F166800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Escitalopram and its metabolite are excreted into breast milk. Limited data is available concerning the effects escitalopram may have in the nursing infant and the long-term effects on development and behavior have not been studied. Adverse effects have been reported in nursing infants exposed to some SSRIs. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Maternal use of an SSRI during pregnancy may cause delayed milk secretion. Escitalopram is the S-enantiomer of the racemic derivative citalopram; also refer to the Citalopram monograph.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F166801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Escitalopram Oxalate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (240 mL): $190.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lexapro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (240 mL): $272.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Escitalopram Oxalate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $450.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $441.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $460.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lexapro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $546.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $571.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $595.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; akathisia; signs/symptoms of serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cipralex (AE, AT, BG, BH, CH, CY, CZ, DE, DK, EE, EG, ES, FI, GB, GR, ID, IE, IL, IN, IQ, IR, IT, JO, KW, LB, LY, NO, OM, PK, PL, PT, QA, RU, SA, SE, SY, TR, YE);",
"     </li>",
"     <li>",
"      Citalo (KP);",
"     </li>",
"     <li>",
"      Citao (TW);",
"     </li>",
"     <li>",
"      Citaplex (KP);",
"     </li>",
"     <li>",
"      E-Zentius (PE);",
"     </li>",
"     <li>",
"      Edpa (KP);",
"     </li>",
"     <li>",
"      Epram (TW, UY);",
"     </li>",
"     <li>",
"      Escital (KP);",
"     </li>",
"     <li>",
"      Esipram (AU);",
"     </li>",
"     <li>",
"      Eslopran (CO);",
"     </li>",
"     <li>",
"      Estimex (PY);",
"     </li>",
"     <li>",
"      Esto (IL);",
"     </li>",
"     <li>",
"      Feliz S (PH);",
"     </li>",
"     <li>",
"      Ipran (CN, CO);",
"     </li>",
"     <li>",
"      Jovia (PH);",
"     </li>",
"     <li>",
"      L-Xapam (KP);",
"     </li>",
"     <li>",
"      Leeyo (TW);",
"     </li>",
"     <li>",
"      Lepax (TW);",
"     </li>",
"     <li>",
"      Lexacure (KP);",
"     </li>",
"     <li>",
"      Lexam (AU);",
"     </li>",
"     <li>",
"      Lexapam (KP);",
"     </li>",
"     <li>",
"      Lexapro (AR, AU, BB, BM, BR, BS, BZ, CL, CR, DO, EC, GT, GY, HK, HN, IE, JM, KP, MY, NI, NL, NZ, PA, PE, PH, PR, SG, SR, SV, TH, TT, TW, VE);",
"     </li>",
"     <li>",
"      Lexatin (KP);",
"     </li>",
"     <li>",
"      Lexcitam (KP);",
"     </li>",
"     <li>",
"      Newpram (KP);",
"     </li>",
"     <li>",
"      Recita (IN);",
"     </li>",
"     <li>",
"      Saropram (KP);",
"     </li>",
"     <li>",
"      Seroplex (FR);",
"     </li>",
"     <li>",
"      Sipralexa (BE);",
"     </li>",
"     <li>",
"      Talopram (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Escitalopram is the S-enantiomer of the racemic derivative citalopram, which selectively inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. It has no or very low affinity for 5-HT",
"     <sub>",
"      1-7",
"     </sub>",
"     , alpha- and beta-adrenergic, D",
"     <sub>",
"      1-5",
"     </sub>",
"     , H",
"     <sub>",
"      1-3",
"     </sub>",
"     , M",
"     <sub>",
"      1-5",
"     </sub>",
"     , and benzodiazepine receptors. Escitalopram does not bind to or has low affinity for Na",
"     <sup>",
"      +",
"     </sup>",
"     , K",
"     <sup>",
"      +",
"     </sup>",
"     , Cl",
"     <sup>",
"      -",
"     </sup>",
"     , and Ca",
"     <sup>",
"      ++",
"     </sup>",
"     ion channels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8-12 weeks after initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20 L/kg (S&oslash;gaard, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~56% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 and 3A4 to S-desmethylcitalopram (S-DCT); S-DCT is metabolized to S-didesmethylcitalopram (S-DDCT) via CYP2D6;",
"     <i>",
"      in vitro",
"     </i>",
"     data suggest metabolites do not contribute significantly to the antidepressant effects of escitalopram",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~27-32 hours (increased ~50% in the elderly and doubled in patients with hepatic impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Escitalopram: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (8% as unchanged drug; S-DCT 10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernard L, Stern R, Lew D, et al, &ldquo;Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(9):1197.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/12715317/pubmed\" id=\"12715317\" target=\"_blank\">",
"        12715317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter JS, Guthrie KA, Larson JC, et al, \"Effect of Escitalopram on Hot Flash Interference: A Randomized, Controlled Trial,\"",
"      <i>",
"       Fertil Steril",
"      </i>",
"      ,  2012, 97(6):1399-1404.e1",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/22480818/pubmed\" id=\"22480818\" target=\"_blank\">",
"        22480818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Defronzo Dobkin R, Menza M, Allen LA, et al, \"Escitalopram Reduces Hot Flashes in Nondepressed Menopausal Women: A Pilot Study,\"",
"      <i>",
"       Ann Clin Psychiatry",
"      </i>",
"      , 2009, 21(2):70-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/19439155/pubmed\" id=\"19439155\" target=\"_blank\">",
"        19439155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman EW, Guthrie KA, Caan B, et al, \"Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial,\"",
"      <i>",
"       JAMA.",
"      </i>",
"      2011, 305(3):267-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/21245182/pubmed\" id=\"21245182\" target=\"_blank\">",
"        21245182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahlberg R, Kunz D, Sasse J, et al, &ldquo;Serotonin Syndrome With Tramadol and Citalopram,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2004, 161(6):1129.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montgomery SA, Loft H, Sanchez C, et al, &ldquo;Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted From a Rat Model,&rdquo;",
"      <i>",
"       Pharmacol Toxicol",
"      </i>",
"      , 2001, 88(5):282-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/11393591/pubmed\" id=\"11393591\" target=\"_blank\">",
"        11393591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&oslash;gaard B, Mengel H, Rao N, et al, &ldquo;The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(12):1400-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/16291715/pubmed\" id=\"16291715\" target=\"_blank\">",
"        16291715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tahir N, &ldquo;Serotonin Syndrome as a Consequence of Drug-Resistant Infections: An Interaction Between Linezolid and Citalopram,",
"      <i>",
"       J Am Med Dir Assoc",
"      </i>",
"      , 2004, 5(2):111-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tseng PT, Lee Y, Lin YE, et al, &ldquo;Low-Dose Escitalopram for 2 Days Associated With Corrected QT Interval Prolongation in a Middle-Aged Woman: A Case Report and Literature Review,&rdquo;",
"      <i>",
"       Gen Hosp Psychiatry",
"      </i>",
"      , 2012, 34(2):210.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/22133983/pubmed\" id=\"22133983\" target=\"_blank\">",
"        22133983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al, &ldquo;Escitalopram (S-Citalopram) and its Metabolites",
"      <i>",
"       in vitro",
"      </i>",
"      : Cytochromes Mediating Biotransformation, Inhibitory Effects, and Comparison to R-Citalopram,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2001, 29(8):1102-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/11454728/pubmed\" id=\"11454728\" target=\"_blank\">",
"        11454728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang LP and Scott LJ, \"Escitalopram in the Treatment of Major Depressive Disorder in Adolescent Patients,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2010, 12(3):155-63",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/20481645/pubmed\" id=\"20481645\" target=\"_blank\">",
"        20481645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/56/25481/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9046 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25481=[""].join("\n");
var outline_f24_56_25481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13502640\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708748\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166813\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F608961\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166832\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166816\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689783\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166817\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166818\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166819\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166789\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6813990\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166775\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874431\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166792\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685303\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052832\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166830\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166795\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166778\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166826\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166782\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166809\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166784\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166799\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166822\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166800\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166801\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166798\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166786\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166802\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166777\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166794\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/1/44053?source=related_link\">",
"      Escitalopram: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/21/36184?source=related_link\">",
"      Escitalopram: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25482="Epidemiology and risk factors for cutaneous squamous cell carcinoma";
var content_f24_56_25482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Jean Lee Lim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Maryam Asgari, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25482/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/56/25482/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/56/25482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous squamous cell carcinoma (SCC) is a common cancer arising from malignant proliferation of epidermal keratinocytes. The likelihood of developing SCC is dependent upon exposure to risk factors (most importantly ultraviolet light) and patient-specific characteristics, such as age, skin type, and ethnicity.",
"   </p>",
"   <p>",
"    The epidemiology and risk factors of cutaneous SCC will be reviewed here. The clinical features, diagnosis, treatment, and prognosis of cutaneous SCC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous SCC is the second most common type of skin cancer in the United States, behind basal cell carcinoma (BCC), and accounts for approximately 20 percent of nonmelanoma skin cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].&nbsp;Because cutaneous SCCs are not typically reported to cancer registries, the exact incidence of this malignancy is unknown.",
"   </p>",
"   <p>",
"    Epidemiologic studies often combine data on SCC, BCC, and other nonmelanocytic skin tumors. Such studies have yielded widely variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. One of the highest incidence rates reported in the United States is from a population-based study that utilized governmental data on skin cancer procedures and skin cancer-related office visits to estimate the number of new skin cancer diagnoses in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/4\">",
"     4",
"    </a>",
"    ]. The authors estimated that more than 3.5 million cases of invasive SCC, SCC in situ, BCC, and other less common nonmelanoma skin cancers occurred in 2006. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of cutaneous SCC has increased over the past 20 years in the United States and other countries. This increase may be related to higher levels of sun exposure, tanning bed use, an increase in the aging population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/6\">",
"     6",
"    </a>",
"    ], and improved skin cancer detection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Epidemiologic factors such as geographic location and ethnicity also appear to influence risk for cutaneous SCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Geographic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-adjusted annual incidence of cutaneous SCC in the United States varies according to latitude. For example, the incidence of SCC is higher in Arizona than in New Hampshire (270 versus 97 per 100,000 in men and 110 versus 32 per 100,000 in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar pattern of geographic variability exists globally with a higher incidence of cutaneous SCC closer to the equator. In Australia, for example, there are approximately 1035 and 472 cases per 100,000 for men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, the age-adjusted incidences for men and women in Finland are only about 6 and 4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cutaneous SCC increases dramatically with age. It is infrequent in those under 45 years of age, although the incidence of cutaneous SCC is increasing significantly in young individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/15\">",
"     15",
"    </a>",
"    ]. For those over 75, the incidence is approximately 5 to 10 times higher than the incidence in younger age groups and 50 to 300 times higher than for those under 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blacks, dark-skinned Asians, and other people with skin of color have low reported rates of cutaneous SCC, whereas light-skinned, non-Hispanic white populations have the highest reported rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. While the incidence of SCC in non-Hispanic white women and men in the United States has been estimated to be as high as 150 and 360 per 100,000 individuals, respectively, the incidence in black individuals is estimated to be 3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/19\">",
"     19",
"    </a>",
"    ]. In dark-skinned people, SCC tends to arise on non sun-exposed areas and is frequently associated with chronic inflammation, chronic wounds, or scarring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link&amp;anchor=H574142#H574142\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\", section on 'Location'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both environmental and genetic factors contribute to the development of cutaneous SCC. Among light-skinned individuals, the most important risk factors are cumulative sun (UV light) exposure and age. Furthermore, sun exposure increases the likelihood of cutaneous SCC in the presence of other risk factors (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     UV light exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) radiation is absorbed by DNA and can result in DNA damage. If the damage is not repaired, a series of changes can result in malignant transformation. In particular, the p53 tumor suppressor gene often has point mutations specifically associated with damage caused by UVB radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/20\">",
"     20",
"    </a>",
"    ]. An estimated 45 to 60 percent of SCCs have p53 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     UVB radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies indicate that cumulative sun exposure (principally UVB radiation) is the most important environmental cause of cutaneous SCC. In contrast, intense intermittent sun exposure (eg, sunburn, childhood exposure) is the most important risk factor for BCC and melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/16,23-25\">",
"     16,23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors for the development of melanoma\", section on 'Sun exposure and UV radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a case control study of 58 patients with cutaneous SCC, the risk was greatest in those with more than 30,000 hours of cumulative lifetime sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/26\">",
"     26",
"    </a>",
"    ]. Age greater than 60 years was an independent risk factor, suggesting that tumor latency and other age-related changes (eg, decreased immune surveillance) also play a role.",
"   </p>",
"   <p>",
"    Other factors associated with an increased risk of cutaneous SCC and consistent with a causative role for UVB radiation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of sun exposure in the past 5 to 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Occupational sun exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Phenotypic characteristics such as fair skin, light-colored eyes, red hair, and Northern European origin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/28,30-32\">",
"       28,30-32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     UVA radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although UVB is thought to be the primary factor in causing cutaneous SCC, UVA also has an etiologic role.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PUVA use (psoralen and UVA light therapy) is associated with an increase in the incidence of cutaneous SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. This risk was illustrated in a 30-year prospective study of a cohort of 1380 psoriasis patients who received PUVA phototherapy. There was more than a 35-fold increase in the rate of cutaneous SCC among those who had received more than 450 PUVA treatments (incidence rate ratio = 37.7, 95% CI 25.6-55.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tanning beds, which primarily emit UVA radiation, cause skin changes like those seen with sun damage. Observational studies suggest that the use of tanning beds increases the risk of both cutaneous SCC and BCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. A 2012 meta-analysis of observational studies found a 67 percent higher risk for SCC among subjects with a history of any tanning bed use compared with subjects who had never used tanning beds (relative risk = 1.67, 95% CI 1.29-2.17) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of sunless tanning creams suggest that there is no increase in the risk of skin tumors associated with use of these agents if proper sun protection is concurrently used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation (such as that used for acne, tinea capitis, and cancer), grenz-rays (used for psoriasis and other skin diseases), and gamma rays are associated with the development of SCC and BCC. The risk associated with radiation exposure is dose-related and higher in sites that have the most sun exposure. The basal layer of the epidermis is more affected by radiation than the more superficial layers, with a higher relative risk of BCC compared to cutaneous SCC in exposed groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, there was an excess risk of BCC but not cutaneous SCC in Japanese survivors of the atomic bomb [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have reported a significantly increased risk of cutaneous SCC as well as BCC. In a Canadian population-based case control study, men exposed to nondiagnostic radiation had a fivefold increased risk of cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/44\">",
"     44",
"    </a>",
"    ]. In another report, there was a threefold increased risk associated with exposure to therapeutic ionizing radiation, although this effect was limited to those who also reported sun-sensitive skin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic immunosuppression (eg, secondary to solid organ transplantation, HIV infection, or long-term glucocorticoid use) may increase the incidence of cutaneous SCC, and to a lesser extent, BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. In the Netherlands and Norway, the rates of cutaneous SCC were 65 to 250 times more frequent in kidney and heart recipients than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In the United States, approximately 35 percent of heart transplant recipients will develop a skin cancer within 10 years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. The risk of multiple lesions is high. Among heart transplant patients who have had one post-transplant SCC or BCC, 60 to 70 percent will develop a subsequent SCC within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=see_link&amp;anchor=H7860393#H7860393\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Squamous cell and basal cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of cutaneous SCC increases with the duration and degree of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and is higher in sunny climates. About 45 percent of transplant patients in Australia report a cutaneous SCC within 10 years after transplantation compared to 10 to 15 percent of patients from Holland, England, or Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenic mechanisms in these patients are multifactorial, with a history of sun exposure preceding or following transplantation being the most important risk factor. In a study of 5356 transplant recipients in Sweden, the relative risk of nonmelanoma skin cancer was about 40 times higher on the lips compared to other epithelial tissues (eg, mouth, anus, rectum) that are not highly sun exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DNA damage caused by UV radiation may be augmented by both direct effects of immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/55\">",
"     55",
"    </a>",
"    ] and decreased immune surveillance that results in a reduced ability to eradicate precancerous changes in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, cutaneous SCCs are more aggressive in transplant recipients as evidenced by an increased risk of local recurrence, regional and distant metastasis, and mortality compared to other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294558#H2294558\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to UV exposure, a common polymorphism in the folate pathway has recently been associated with an increased risk of cutaneous SCC in transplant patients. In a cohort of 367 renal transplant patients, those who carried the polymorphism MTHFR:C677T had a statistically significant increased risk of developing a SCC (OR = 2.54) compared to those who did not have the polymorphism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/56\">",
"     56",
"    </a>",
"    ]. This folate polymorphism has also been linked to other malignancies including colon cancer, pancreatic cancer, and leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of cutaneous SCC in chronically inflamed skin resulting from scars, burns, chronic ulcers, sinus tracts, or inflammatory dermatoses such as lichen sclerosus et atrophicus. When a cutaneous SCC occurs in a chronic wound, it is also known as Marjolin's ulcer. Lichen sclerosus et atrophicus is a scarring inflammatory skin condition typically involving the female genitals and is associated with cutaneous SCC and verrucous carcinoma of the vulva. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 1 percent of cutaneous skin cancers arise in chronically inflamed skin and about 95 percent of these are SCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/57\">",
"     57",
"    </a>",
"    ]. The interval between the initial skin damage and appearance of a tumor varies widely, with SCC appearing as early as six weeks or as many as 60 years after the traumatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arsenic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic exposure to arsenic is associated with a variety of cancers. Consumption of contaminated drinking water and occupational exposure are associated with cutaneous SCC and BCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link&amp;anchor=H11#H11\">",
"     \"Arsenic exposure and poisoning\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk associated with arsenic exposure is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Taiwan, the incidence of cutaneous SCC was significantly increased two- to fourfold among individuals who lived in towns with well water with arsenic levels above 0.64",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      compared to those whose towns had no wells with arsenic levels above 0.04",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from New Hampshire, individuals with the highest toenail arsenic concentration (&gt;97th percentile) had a twofold increase in risk of cutaneous SCC that was not seen among those with more moderate levels of arsenic exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H567389\">",
"    <span class=\"h2\">",
"     Genetic alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to UV-induced mutations in the p53 tumor suppressor gene, other genetic alterations may contribute to the development of SCC. Increased development of SCCs (most commonly keratoacanthomas, which may represent a variant of SCC) has been detected in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and other chemotherapeutic agents that inhibit RAF, and mutations in exons of the CDKN2A locus and RAS pathways have also been linked to SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/22,63\">",
"     22,63",
"    </a>",
"    ]. It is hypothesized that genetic alterations may allow keratinocytes to resist UV-induced apoptosis leading to clonal expansion, selective growth advantage, and in certain cases, the development of invasive or metastatic capability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/22,63,64\">",
"     22,63,64",
"    </a>",
"    ]. Additional studies are necessary to elucidate the roles of these factors in cutaneous SCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H11#H11\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Squamoproliferative lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a family history of SCC may have an increased risk for developing the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. In a cohort study of more than 11 million individuals in Sweden that included 3867 cases of invasive SCCs, subjects with a sibling or parent who had a history of invasive SCC were two to three times as likely to develop the same diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/65\">",
"     65",
"    </a>",
"    ]. A smaller study of 25,882 adults in Finland found a lack of correlation of SCC among twins. However, the number of cases of SCC in the study was low; only 43 SCCs were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are necessary to explore the role of family history in risk for SCC. Similar cutaneous phenotypes, shared environmental exposures, and genetic factors are among the potential contributors to familial risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inherited disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Xeroderma pigmentosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xeroderma pigmentosum (XP) is a rare disorder in which there is an impaired ability to repair UV-induced DNA damage. XP is a multigenic, multialleic autosomal recessive disease that occurs at a frequency of approximately 1 in 250,000. Mutations in eight genes have been identified. Seven of these genes (ie, XPA to XPG) are involved in nucleotide excision repair of carcinogen adducts after UV irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/68-70\">",
"     68-70",
"    </a>",
"    ], while the other (ie, XPV) is involved in error-free replication of DNA damaged by UV irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/68\">",
"     68",
"    </a>",
"    ]. XPV is due to mutations in the DNA polymerase eta or hRAD30 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link&amp;anchor=H12#H12\">",
"     \"Inherited susceptibility to melanoma\", section on 'Xeroderma pigmentosum genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    XP homozygotes have severe sun sensitivity that leads to degeneration of the skin and eyes and the development of cutaneous SCCs, BCCs, and melanomas beginning in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Associated ocular abnormalities include keratitis, opacification of the cornea, iritis with synechia formation, and melanoma of the choroid.",
"   </p>",
"   <p>",
"    In individuals with XP, the incidence of skin cancers prior to the age of 20 years is approximately 2000 times that seen in the general population. In a retrospective study of 132 patients, there was a 57 percent lifetime prevalence of nonmelanoma skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/75\">",
"     75",
"    </a>",
"    ]. The median age at the diagnosis of the first tumor was eight years, with a ratio of SCC to BCC of about 1 to 2.",
"   </p>",
"   <p>",
"    In addition, a variety of neurologic abnormalities have been associated with XP. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H25#H25\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermolysis bullosa (EB) syndromes are a group of mechanobullous skin diseases that share a common feature of blister formation occurring with little or no trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"     \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from the National EB Registry indicate that patients with recessive dystrophic EB (RDEB), and particularly those with the Hallopeau-Siemens subtype of RDEB (HS-RDEB), are at increased risk of squamous cell carcinoma beginning in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/76\">",
"     76",
"    </a>",
"    ]. For patients with HS-RDEB, the cumulative risk for squamous cell carcinoma was 7.5 percent by age 20 and 90 percent by age 55 years. Only 10 percent of these SCCs arose in sun-exposed regions and the majority occurred in long-term skin wounds.",
"   </p>",
"   <p>",
"    Although these SCCs are well differentiated, they are biologically aggressive, with a high incidence of metastases. The cumulative risk of death from squamous cell carcinoma was 80 percent by age 55 years, despite aggressive surgical resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Albinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculocutaneous albinism consists of at least 10 different inherited skin diseases characterized by a generalized decrease of pigmentation in the skin, eyes, and hair due to abnormal melanocyte function. Individuals with albinism must protect themselves from sunlight, or they risk the early development of both cutaneous SCC and BCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H19#H19\">",
"     \"The genodermatoses\", section on 'Oculocutaneous albinism (OCA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 111 South African black albinos, the point prevalence of nonmelanoma skin cancer was about 25 percent, with increasing risk of skin tumors with increased age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/77\">",
"     77",
"    </a>",
"    ]. Without sun protection, albinos have shortened life expectancy. In Africa, few albinos live past 40 years due to death from metastatic SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174208\">",
"    <span class=\"h2\">",
"     Epidermodysplasia verruciformis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermodysplasia verruciformis is a rare disease characterized by extreme susceptibility to cutaneous human papillomavirus (HPV) strains 5 and 8 and cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'HPV infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4027866\">",
"    <span class=\"h3\">",
"     Other genetic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other rare genetic disorders are associated with increased incidence of SCC and younger age of onset including Fanconi&rsquo;s anemia, Ferguson-Smith Syndrome (keratoacanthomas), dyskeratosis congenita, Rothmund-Thomson syndrome, Bloom syndrome, and Werner syndrome. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although individual epidemiologic studies have yielded conflicting results about the role of smoking as a risk factor for cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/30,80-82\">",
"     30,80-82",
"    </a>",
"    ], a 2012 systematic review and meta-analysis of cohort and case control studies found a statistically significant association between smoking and risk for cutaneous SCC (OR 1.52, 95% CI 1.15-2.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/83\">",
"     83",
"    </a>",
"    ]. The results of the meta-analysis indicate a strong association between smoking and cutaneous SCC, but are insufficient to confirm smoking as a causative factor. Further studies are necessary to determine the rationale for this association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have shown conflicting results about the role of diet as a risk factor for cutaneous SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. A prospective study of 1360 adults in Australia suggested that a diet high in meat and fat significantly increased the risk of SCC (RR = 3.77; 95% CI 1.65-8.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/84\">",
"     84",
"    </a>",
"    ]. In another prospective study (n = 1057), high fat intake elevated the risk for SCC only among patients with a prior history of skin cancer (RR = 2.94; 95% CI 1.20-4.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a separate case control and prospective study of 195 patients with cutaneous SCC showed no evidence that high fat intake increases the risk of developing SCC. In fact, at the highest levels of fat intake, the odds of developing cutaneous SCC showed a trend toward reduced risk (OR = 0.70; 95% CI = 0.45-1.10, p = 0.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     HPV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) infection can cause cutaneous SCC in genetically predisposed individuals (eg, epidermodysplasia verruciformis) and verrucous carcinoma of the penis (Bushke-Lowenstein tumor).",
"   </p>",
"   <p>",
"    However, HPV infections in skin are common, and studies conflict on the relationship between HPV and cutaneous SCC in the general population. Multiple studies have reported indirect evidence supporting an etiologic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/87-93\">",
"     87-93",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case control study of 252 patients with cutaneous SCC and 461 age-matched controls; HPV antibodies were significantly more frequent in patients with SCC than in controls (63 versus 52 percent; odds ratio 1.6, 95% CI 1.2 to 2.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study that compared tissue samples from patients with and without SCC found that although HPV DNA was found in similar proportions of lesions of SCC and normal skin specimens from the control population, DNA from the betapapillomavirus subtype of HPV was more likely to be present in tumoral skin than in healthy skin adjacent to tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a study that compared HPV viral loads and HPV mRNA expression in tumoral and normal tissue found no difference in HPV viral loads between tumors and healthy tissue from individuals without SCC and failed to detect HPV mRNA expression in skin tumors. These results suggest that HPV may not be involved in the maintenance of SCC lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/94\">",
"     94",
"    </a>",
"    ]. Additional studies are necessary to clarify whether the association between cutaneous SCC and HPV is clinically relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports and small series, long-term therapy with the antifungal drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has been associated with the development of SCC in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/95-99\">",
"     95-99",
"    </a>",
"    ]. One series of eight patients who developed SCC during voriconazole therapy included two children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The drug also can cause cutaneous photosensitivity, but the mechanism through which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    might contribute to the occurrence of SCC remains unknown. Voriconazole-induced phototoxic eruptions were documented in almost all of the patients who developed SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/95-99\">",
"     95-99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H22#H22\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Phototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535455\">",
"    <span class=\"h3\">",
"     BRAF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 15 and 30 percent of patients treated with BRAF inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    and dabrafenib, develop SCCs or keratoacanthomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/100\">",
"     100",
"    </a>",
"    ]. The first lesions typically appear within weeks of the start of therapy. This occurrence may be related to a paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in cells harboring preexisting RAS or receptor tyrosine kinase mutations, an event that may contribute to the proliferation and survival of cancerous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=see_link&amp;anchor=H5643627#H5643627\">",
"     \"The molecular biology of melanoma\", section on 'BRAF inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45395983\">",
"    <span class=\"h3\">",
"     ABO blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood type may influence the risk for SCC. In a cohort study of 71,000 women and 25,000 men, the risk of developing an SCC was 14 percent lower among patients with A, AB, or B blood types compared to those with type O blood (HR 0.86, 95% CI 0.78-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/101\">",
"     101",
"    </a>",
"    ]. The reason for this observation is unknown, and additional studies are necessary to confirm this finding. Associations between blood type and risks for basal cell carcinoma and pancreatic cancer also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H2896064#H2896064\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Blood type'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link&amp;anchor=H18033984#H18033984\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'ABO blood group'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-control studies have reported an increased risk of SCC among women with a history of oral contraceptive use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. However, confounding variables may have contributed to these results, and further studies are necessary to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double blind trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    among those with a prior history of nonmelanoma skin cancer suggested that there was an increased risk of cutaneous SCC associated with dietary selenium supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2872158\">",
"    <span class=\"h3\">",
"     Radon",
"    </span>",
"    &nbsp;&mdash;&nbsp;High concentrations of environmental radon were associated with increased rates of cutaneous SCC in a study in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/106\">",
"     106",
"    </a>",
"    ]. Locations with the highest radon concentrations had an almost two-fold increase in reported cutaneous SCCs compared with areas with the lowest radon concentrations (relative risk 1.76, 95% CI 1.46-2.11). Additional studies are necessary to confirm an effect of radon exposure on risk for cutaneous SCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Protection from sun exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection from the sun, including the application of sunscreen and the use of protective clothing, reduces the risk of cutaneous SCC and its precursor lesion, actinic keratosis.",
"   </p>",
"   <p>",
"    Even relatively short-term use of sunscreen can be beneficial, as illustrated by two randomized trials from Australia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects who used SPF 17 sunscreen for one summer had a statistically significantly decreased number of new actinic keratoses (relative risk = 0.6 compared to placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/107\">",
"       107",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link\">",
"       \"Epidemiology, natural history, and diagnosis of actinic keratosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Daily use of SPF 15 sunscreen for 4.5 years was associated with a significantly lower incidence of SCCs (1115 versus 1832 per 100,000, compared to no daily sunscreen) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/108\">",
"       108",
"      </a>",
"      ]. In contrast, no difference was observed in the incidence of BCCs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to preventing sun exposure is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Organ transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic immunosuppressive therapy increases the risk for nonmelanoma skin cancer in organ transplant recipients. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Immunosuppression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of daily sun protective measures may decrease the incidence of actinic keratoses and SCC in this population. In a non-randomized controlled study of 120 organ transplant recipients, participants using daily sunscreen developed fewer actinic keratoses and SCCs than subjects with intermittent sunscreen use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/109\">",
"     109",
"    </a>",
"    ]. Despite the small sample size in this study, organ transplant recipients should be strongly encouraged to comply with sun protective measures, including the use of daily sunscreen.",
"   </p>",
"   <p>",
"    Squamous cell carcinoma in organ transplant recipients is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=see_link\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link\">",
"     \"Management of skin cancer in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Oral retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoids are vitamin A derivatives that are available in topical and oral preparations. Oral retinoids inhibit SCC cell growth in vitro and may reduce the development of cutaneous SCC tumors in high-risk populations such as those with a history of multiple nonmelanoma skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], genetic disorders such as xeroderma pigmentosum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/112,113\">",
"     112,113",
"    </a>",
"    ], transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/114,115\">",
"     114,115",
"    </a>",
"    ], and patients exposed to high cumulative levels of PUVA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of studies that have evaluated the use of oral retinoids for the prevention of SCC include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 2297 adults with a prior history of &gt;10 actinic keratoses or &ge;2 cutaneous SCCs were randomly assigned to 25,000 international units of oral retinol daily or a placebo. At an average follow-up of four years, the active treatment group had a significantly lower rate of new cutaneous SCCs (hazard ratio = 0.74) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/111\">",
"       111",
"      </a>",
"      ]. However, this dose of retinol was associated with an 11 percent higher triglyceride level and 3 percent higher cholesterol level, which may increase coronary artery disease risk [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/117\">",
"       117",
"      </a>",
"      ]. Of note, a smaller randomized trial of 525 patients treated with oral retinol (25,000 units per day),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      (5 to 10 mg per day), or placebo for three years found a lack of benefit with both retinol and isotretinoin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In five patients with xeroderma pigmentosum, 121 tumors occurred in the two-year interval before treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      compared to 25 in the two years during treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/112\">",
"       112",
"      </a>",
"      ]. Following cessation of therapy, there was an 8.5-fold increase in tumor frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Randomized trials have found variable results for the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      as a chemopreventive agent in organ transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/119\">",
"       119",
"      </a>",
"      ]. Data from these trials is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294628#H2294628\">",
"       \"Management of skin cancer in solid organ transplant recipients\", section on 'Acitretin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among psoriasis patients treated with PUVA, the use of oral retinoids for at least 26 weeks per year was associated with a significantly decreased incidence of cutaneous SCC compared to less frequent retinoid use (196",
"      <span class=\"nowrap\">",
"       SCCs/1000",
"      </span>",
"      years versus",
"      <span class=\"nowrap\">",
"       302/1000",
"      </span>",
"      years, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/116\">",
"       116",
"      </a>",
"      ]. The benefit was restricted to periods of high usage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Topical retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large, multicenter, randomized trial (n = 1131) sought to investigate the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    on the prevention of SCC and BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/120\">",
"     120",
"    </a>",
"    ]. Patients were treated with tretinoin 0.1% cream or a vehicle control for 1.5 to 5.5 years. Treatment with tretinoin was not effective for chemoprevention in this trial; statistically significant differences in the proportions of patients who had developed an invasive SCC (28 versus 31 percent) or a BCC (53 versus 54 percent) after five years were not detected. The trial was terminated prematurely due to an increase in mortality observed in the treatment group. However, the authors questioned the validity of this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of actinic keratosis\", section on 'Retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous clinical studies have examined the relationship between the other agents and the development of nonmelanoma skin cancer. The findings with several agents include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies in animal models suggest that nonsteroidal antiinflammatory drugs (NSAIDs) may prevent the development of cutaneous SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/122-124\">",
"       122-124",
"      </a>",
"      ]; however, human studies have led to conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/122,125-127\">",
"       122,125-127",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An 11-month randomized trial (n = 240) that investigated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      (200 mg twice daily for nine months) as a chemoprotective agent for actinic keratoses found no difference in the incidence of actinic keratoses in the treated and placebo groups, but found that fewer SCCs developed in patients treated with celecoxib (adjusted rate ratio = 0.42, 95% CI 0.19 to 0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large population-based case-control study in Denmark supported the concept that NSAIDs are protective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/127\">",
"       127",
"      </a>",
"      ]. Patients with a history of use of any NSAID (more than two prescriptions) had a reduced risk for SCC (incidence rate ratio = 0.85, 95% CI 0.76-0.94) when compared with patients with lesser NSAID use. Nonprescription NSAID use and variables such as UV exposure, skin type, drug dose, and lifestyle factors were not accounted for in this study. In addition, a large proportion of SCCs in Denmark (around 40 percent) are not reported to the Danish Cancer Registry, a factor that could contribute to overestimation or underestimation of the association between NSAIDs and SCC risk.",
"     </li>",
"     <li>",
"      A case control study of 86 patients with SCC and 187 controls found a significant decrease in the risk of actinic keratoses and SCC in those regularly using NSAIDs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/122\">",
"       122",
"      </a>",
"      ]. In contrast, the results of a larger case control study (n = 830) did not identify an association between NSAID use and risk for SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are necessary to explore the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and other NSAIDs for the prevention of SCC and to determine whether beneficial effects on SCC risk would outweigh the risks of long term therapy with NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/128\">",
"     128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H5#H5\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Celecoxib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of an older Southwestern population suggested that consumption of D-limonene found in citrus peels and hot black tea was associated with decreased cutaneous SCC risk [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/129\">",
"       129",
"      </a>",
"      ]. In contrast, a case control study of 415 patients with SCC and their matched controls showed no reduction of SCC risk amongst those who regularly consumed tea [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Randomized trials",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      supplementation for cutaneous SCC prevention showed no protective effect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/108,131,132\">",
"       108,131,132",
"      </a>",
"      ], and two large prospective cohort studies concluded that vitamin A, C, E, and folate have no effect in preventing SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-reported use of grape seed extract as a dietary supplement was associated with a reduced risk for cutaneous SCC in a study of 415 patients with SCC and their matched controls (adjusted odds ratio = 0.26, 95% CI 0.08-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/56/25482/abstract/134\">",
"       134",
"      </a>",
"      ]. Further studies are necessary to corroborate these findings prior to a recommendation for the use of grape seed extract for this indication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"       \"Patient information: Skin cancer (non-melanoma) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"       \"Patient information: Sunburn (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/8/19586?source=see_link\">",
"       \"Patient information: Actinic keratosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       \"Patient information: Sunburn (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCC is a common skin malignancy and its incidence is increasing worldwide. SCC incidence varies widely in different areas, with the highest incidence in areas of increased sun exposure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary risk factor for cutaneous SCC is UV light exposure. UV light damages DNA, initiating a series of changes can result in malignant transformation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'UV light exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risk factors that interact with UV light exposure include having skin that burns easily and does not tan or tans poorly, light-colored hair, northern European ancestry, older age, exposure to PUVA phototherapy, immunosuppressive treatment, exposure to radiation and other industrial carcinogens, and smoking. Chronic inflammation and rare inherited disorders also are associated with an increased risk of cutaneous SCC. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of cutaneous SCC can be substantially reduced by limiting sun exposure and using sunscreen, hats, and sun-protective clothing. Chemoprevention does not have an established role, although retinoids may have some activity. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Cancer Society. Cancer facts and figures 2003 www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&amp;level=1 (Accessed on April 01, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/2\">",
"      Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/3\">",
"      Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/4\">",
"      Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society Cancer Facts and Figures 2010. file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf (Accessed on October 04, 2010).",
"    </li>",
"    <li>",
"     Aging Statistics. file://www.aoa.gov/aoaroot/aging_statistics/index.aspx.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/7\">",
"      Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol 1995; 22:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/8\">",
"      Hacker SM, Flowers FP. Squamous cell carcinoma of the skin. Will heightened awareness of risk factors slow its increase? Postgrad Med 1993; 93:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/9\">",
"      Karagas MR, Greenberg ER, Spencer SK, et al. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999; 81:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/10\">",
"      Gray DT, Suman VJ, Su WP, et al. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/11\">",
"      Chuang TY, Reizner GT, Elpern DJ, et al. Squamous cell carcinoma in Kauai, Hawaii. Int J Dermatol 1995; 34:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/12\">",
"      Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001; 45:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/13\">",
"      Green A, Battistutta D, Hart V, et al. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol 1996; 144:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/14\">",
"      Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999; 135:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/15\">",
"      Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/16\">",
"      Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/17\">",
"      Koh D, Wang H, Lee J, et al. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry data 1968-97. Br J Dermatol 2003; 148:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/18\">",
"      Halder RM, Bang KM. Skin cancer in blacks in the United States. Dermatol Clin 1988; 6:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/19\">",
"      Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/20\">",
"      de Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001; 63:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/21\">",
"      Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991; 88:10124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/22\">",
"      Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet 2004; 131C:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/23\">",
"      Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/24\">",
"      Vitasa BC, Taylor HR, Strickland PT, et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990; 65:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/25\">",
"      Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer 2006; 94:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/26\">",
"      Vitaliano PP, Urbach F. The relative importance of risk factors in nonmelanoma carcinoma. Arch Dermatol 1980; 116:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/27\">",
"      Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol 1995; 131:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/28\">",
"      Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/29\">",
"      Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/30\">",
"      Grodstein F, Speizer FE, Hunter DJ. A prospective study of incident squamous cell carcinoma of the skin in the nurses' health study. J Natl Cancer Inst 1995; 87:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/31\">",
"      English DR, Armstrong BK, Kricker A, et al. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998; 76:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/32\">",
"      Zanetti R, Rosso S, Martinez C, et al. The multicentre south European study 'Helios'. I: Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/33\">",
"      Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/34\">",
"      Lindel&ouml;f B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/35\">",
"      Stern RS, PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/36\">",
"      Lever LR, Lawrence CM. Nonmelanoma skin cancer associated with use of a tanning bed. N Engl J Med 1995; 332:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/37\">",
"      Roest MA, Keane FM, Agnew K, et al. Multiple squamous skin carcinomas following excess sunbed use. J R Soc Med 2001; 94:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/38\">",
"      Karagas MR, Stannard VA, Mott LA, et al. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst 2002; 94:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/39\">",
"      Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/40\">",
"      Petersen AB, Na R, Wulf HC. Sunless skin tanning with dihydroxyacetone delays broad-spectrum ultraviolet photocarcinogenesis in hairless mice. Mutat Res 2003; 542:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/41\">",
"      Draelos ZD. Self-tanning lotions: are they a healthy way to achieve a tan? Am J Clin Dermatol 2002; 3:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/42\">",
"      Kishikawa M, Koyama K, Iseki M, et al. Histologic characteristics of skin cancer in Hiroshima and Nagasaki: background incidence and radiation effects. Int J Cancer 2005; 117:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/43\">",
"      Yoshinaga S, Hauptmann M, Sigurdson AJ, et al. Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer 2005; 115:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/44\">",
"      Gallagher RP, Bajdik CD, Fincham S, et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 1996; 5:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/45\">",
"      Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000; 136:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/46\">",
"      Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/47\">",
"      Jensen P, Hansen S, M&oslash;ller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/48\">",
"      Lampros TD, Cobanoglu A, Parker F, et al. Squamous and basal cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/49\">",
"      Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/50\">",
"      Silverberg MJ, Leyden W, Warton EM, et al. HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer. J Natl Cancer Inst 2013; 105:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/51\">",
"      Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/52\">",
"      Fortina AB, Piaserico S, Caforio AL, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/53\">",
"      Ramsay HM, Reece SM, Fryer AA, et al. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007; 84:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/54\">",
"      Lindel&ouml;f B, Sigurgeirsson B, G&auml;bel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/55\">",
"      Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005; 353:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/56\">",
"      Laing ME, Dicker P, Moloney FJ, et al. Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Transplantation 2007; 84:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/57\">",
"      Jellouli-Elloumi A, Kochbati L, Dhraief S, et al. [Cancers arising from burn scars: 62 cases]. Ann Dermatol Venereol 2003; 130:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/58\">",
"      Love RL, Breidahl AF. Acute squamous cell carcinoma arising within a recent burn scar in a 14-year-old boy. Plast Reconstr Surg 2000; 106:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/59\">",
"      Akg&uuml;ner M, Barut&ccedil;u A, Yilmaz M, et al. Marjolin's ulcer and chronic burn scarring. J Wound Care 1998; 7:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/60\">",
"      Friedman R, Hanson S, Goldberg LH. Squamous cell carcinoma arising in a Leishmania scar. Dermatol Surg 2003; 29:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/61\">",
"      Guo HR, Yu HS, Hu H, Monson RR. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control 2001; 12:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/62\">",
"      Karagas MR, Stukel TA, Morris JS, et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol 2001; 153:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/63\">",
"      Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/64\">",
"      Black AP, Ogg GS. The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol 2003; 132:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/65\">",
"      Hussain SK, Sundquist J, Hemminki K. The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden. J Invest Dermatol 2009; 129:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/66\">",
"      Mil&aacute;n T, Verkasalo PK, Kaprio J, et al. Malignant skin cancers in the Finnish Twin Cohort: a population-based study, 1976-97. Br J Dermatol 2002; 147:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/67\">",
"      Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 2012; 345:e8076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/68\">",
"      Cleaver JE, Thompson LH, Richardson AS, States JC. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat 1999; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/69\">",
"      Tu Y, Bates S, Pfeifer GP. Sequence-specific and domain-specific DNA repair in xeroderma pigmentosum and Cockayne syndrome cells. J Biol Chem 1997; 272:20747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/70\">",
"      Nakane H, Takeuchi S, Yuba S, et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature 1995; 377:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/71\">",
"      Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 1999; 399:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/72\">",
"      Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 1999; 285:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/73\">",
"      Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/74\">",
"      Lambert WC, Kuo HR, Lambert MW. Xeroderma pigmentosum. Dermatol Clin 1995; 13:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/75\">",
"      Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/76\">",
"      Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009; 60:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/77\">",
"      Kromberg JG, Castle D, Zwane EM, Jenkins T. Albinism and skin cancer in Southern Africa. Clin Genet 1989; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Albinism. In: Color Atlas and Synopsis of Clinical Dermatology, Common and Serious Diseases, 4th ed, McGraw-Hill, New York 2001. p.322.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/79\">",
"      Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/80\">",
"      Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/81\">",
"      Wensveen CA, Bastiaens MT, Kielich CJ, et al. Relation between smoking and skin cancer. J Clin Oncol 2001; 19:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/82\">",
"      Odenbro A, Bellocco R, Boffetta P, et al. Tobacco smoking, snuff dipping and the risk of cutaneous squamous cell carcinoma: a nationwide cohort study in Sweden. Br J Cancer 2005; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/83\">",
"      Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 2012; 148:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/84\">",
"      Ibiebele TI, van der Pols JC, Hughes MC, et al. Dietary pattern in association with squamous cell carcinoma of the skin: a prospective study. Am J Clin Nutr 2007; 85:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/85\">",
"      Granger RH, Blizzard L, Fryer JL, Dwyer T. Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs. BMC Cancer 2006; 6:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/86\">",
"      Ibiebele TI, van der Pols JC, Hughes MC, et al. Dietary fat intake and risk of skin cancer: a prospective study in Australian adults. Int J Cancer 2009; 125:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/87\">",
"      Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008; 128:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/88\">",
"      Forslund O, Ly H, Reid C, Higgins G. A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol 2003; 149:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/89\">",
"      Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/90\">",
"      Struijk L, Bouwes Bavinck JN, Wanningen P, et al. Presence of human papillomavirus DNA in plucked eyebrow hairs is associated with a history of cutaneous squamous cell carcinoma. J Invest Dermatol 2003; 121:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/91\">",
"      Iftner A, Klug SJ, Garbe C, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003; 63:7515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/92\">",
"      Hall L, Struijk L, Neale RE, Feltkamp MC. Re: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/93\">",
"      Paradisi A, Waterboer T, Sampogna F, et al. Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol 2011; 165:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/94\">",
"      Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/95\">",
"      Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/96\">",
"      Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect 2010; 16:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/97\">",
"      Brunel AS, Fraisse T, Lechiche C, et al. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS 2008; 22:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/98\">",
"      Vanacker A, Fabr&eacute; G, Van Dorpe J, et al. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/99\">",
"      McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/100\">",
"      Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/101\">",
"      Xie J, Qureshi AA, Li Y, Han J. ABO blood group and incidence of skin cancer. PLoS One 2010; 5:e11972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/102\">",
"      Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/103\">",
"      Applebaum KM, Nelson HH, Zens MS, et al. Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol 2009; 129:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/104\">",
"      Asgari MM, Efird JT, Warton EM, Friedman GD. Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study. Int J Environ Res Public Health 2010; 7:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/105\">",
"      Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003; 95:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/106\">",
"      Wheeler BW, Allen J, Depledge MH, Curnow A. Radon and skin cancer in southwest England: an ecologic study. Epidemiology 2012; 23:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/107\">",
"      Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/108\">",
"      Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/109\">",
"      Ulrich C, J&uuml;rgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 Suppl 3:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/110\">",
"      DiGiovanna JJ. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001; 36:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/111\">",
"      Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/112\">",
"      Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/113\">",
"      Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/114\">",
"      McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/115\">",
"      Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/116\">",
"      Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/117\">",
"      Cartmel B, Moon TE, Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. Am J Clin Nutr 1999; 69:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/118\">",
"      Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/119\">",
"      Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/120\">",
"      Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/121\">",
"      Weinstock MA, Bingham SF, Lew RA, et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol 2009; 145:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/122\">",
"      Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/123\">",
"      Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/124\">",
"      Wilgus TA, Koki AT, Zweifel BS, et al. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/125\">",
"      Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/126\">",
"      Asgari MM, Chren MM, Warton EM, et al. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol 2010; 146:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/127\">",
"      Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/128\">",
"      Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/129\">",
"      Hakim IA, Harris RB. Joint effects of citrus peel use and black tea intake on the risk of squamous cell carcinoma of the skin. BMC Dermatol 2001; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/130\">",
"      Asgari MM, White E, Warton EM, et al. Association of tea consumption and cutaneous squamous cell carcinoma. Nutr Cancer 2011; 63:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/131\">",
"      Frieling UM, Schaumberg DA, Kupper TS, et al. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol 2000; 136:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/132\">",
"      Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/133\">",
"      Fung TT, Spiegelman D, Egan KM, et al. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. Int J Cancer 2003; 103:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/56/25482/abstract/134\">",
"      Asgari MM, Chren MM, Warton EM, et al. Supplement use and risk of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2011; 65:1145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5337 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25482=[""].join("\n");
var outline_f24_56_25482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Geographic variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      UV light exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - UVB radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - UVA radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arsenic exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H567389\">",
"      Genetic alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inherited disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Xeroderma pigmentosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Albinism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174208\">",
"      Epidermodysplasia verruciformis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4027866\">",
"      - Other genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HPV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535455\">",
"      - BRAF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45395983\">",
"      - ABO blood group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Selenium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2872158\">",
"      - Radon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Protection from sun exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Oral retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Topical retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=related_link\">",
"      Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=related_link\">",
"      Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/8/19586?source=related_link\">",
"      Patient information: Actinic keratosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=related_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1576?source=related_link\">",
"      The molecular biology of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_56_25483="Diagnostic testing hibernation";
var content_f24_56_25483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic testing for hibernating myocardium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Usually not needed*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal left ventricular function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary arteries not suitable for revascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Usually needed*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected CAD/IDCM, being considered for heart",
"transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CAD plus severe left ventricular dysfunction (LVEF &le;0.35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CAD plus dysfunction in patients who are asymptomatic",
"or have heart failure symptoms: mild/minimal angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Individualize&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina or severe stable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anomalous left coronary artery from pulmonary artery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAD: coronary artery disease; IDCM: idiopathic dilated cardiomyopathy; LVEF: left ventricular ejection fraction.",
"     <br>",
"      * Clinical judgment may be needed.",
"      <br>",
"       &bull;&nbsp;Clinical judgment frequently needed.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rahimtoola SH. J Am Coll Cardiol 1997; 30:1701.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25483=[""].join("\n");
var outline_f24_56_25483=null;
var title_f24_56_25484="History in wheeze I";
var content_f24_56_25484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of wheezing due to upper airway diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Postnasal drip syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of postnasal drip, throat clearing, nasal discharge; physical examination shows oropharyngeal secretions or cobblestone appearance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Supraglottitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of sore throat out of proportion to pharyngitis; evidence of supraglottitis on endoscopy or lateral neck roentgenograms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Paradoxical vocal cord motion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Lack of symptomatic response to bronchodilators, presence of stridor plus wheeze in absence of increased P(A-a)02; extrathoracic, variable obstruction on flow-volume loops; paradoxical inspiratory and/or early expiratory adduction of vocal cords on laryngoscopy during wheezing. This syndrome can masquerade as asthma, can be provoked by exercise, often coexists with asthma, and may be secondary to gastroesophageal reflux disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Retropharyngeal abscess",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of stiff neck, sore throat, fever, trauma to posterior pharynx; swelling noted by lateral neck or CT roentgenograms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Laryngotracheal injury due to tracheal cannulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       History of cannulation of trachea by endotracheal or tracheostomy tube; evidence of intra or extrathoracic, variable obstruction on F-V loops, neck/chest roentgenograms, laryngoscopy or bronchoscopy, or all of these. Flow-volume loops with helium and air may reveal large airway obstruction superimposed on underlying small airway disease (eg, COPD).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neoplasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Carcinoid tumor is suspected when there is hemoptysis, unilateral wheeze, or evidence of lobar collapse on chest roentgenogram; bronchogenic carcinoma considered in the same setting in a cigarette smoker; diagnosis is confirmed by bronchoscopy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anaphylaxis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Distinguishing features:",
"       </strong>",
"       Abrupt onset of wheezing with urticaria, angioedema, nausea, diarrhea, and hypotension, especially following insect bite or administration of drug or intravenous contrast; family history. When symptoms occur during or immediately after exercise, consider the diagnosis of exercise-induced anaphylaxis; or food dependent exercise-induced anaphylaxis when symptoms occur after eating (especially wheat) followed by exercise.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25484=[""].join("\n");
var outline_f24_56_25484=null;
var title_f24_56_25485="Acute scrotum disposition";
var content_f24_56_25485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The acute scrotum: suggested disposition and treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Testicular torsion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Indications for surgery:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Suggestive history or physical examination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Similar episodes &gt;2 weeks ago",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            No flow or spermatic cord&nbsp;knot&nbsp;by Doppler ultrasound",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diagnostic uncertainty&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Treatment:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Definitive: surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Temporizing: trial of manual detorsion",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Torsion of appendage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Admission criteria:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Testicular torsion excluded&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Severe pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pain refractory to trial of analgesics and conservative management",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Treatment:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Analgesics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rest",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acute epididymitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Admission criteria:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Testicular torsion excluded",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Severe pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Immunocompromised",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Not tolerating oral medications or noncompliant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Treatment:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Children:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            <p>",
"             If pyuria &gt;3 WBC/hpf or positive culture, or if underlying GU abnormality:",
"            </p>",
"            <p>",
"             Antibiotic course against coliforms*",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            <p>",
"             If no pyuria and negative culture:",
"            </p>",
"            <p>",
"             Antibiotics not required",
"            </p>",
"            <p>",
"             Extensive evaluation not required",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Sexually active adolescents:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Heterosexual: empiric antibiotics (chlamydia, GC)&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Homosexual: empiric antibiotics (chlamydia, GC and coliforms)&bull;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibiotic choices include: Trimethoprim (TMP)-sulfamethoxazole (6-12 mg TMP component/kg per day divided every 12 hours)",
"     <strong>",
"      or",
"     </strong>",
"     cephalexin (25-50 mg/kg per day divided every 6-8 hours).",
"     <br>",
"      &bull; Ceftriaxone (250 mg IM in one dose)",
"      <strong>",
"       plus",
"      </strong>",
"      doxycycline (100 mg PO twice a day for 10 days). Ofloxacin (300 mg PO twice a day for 10 days)",
"      <strong>",
"       or",
"      </strong>",
"      levofloxacin (500 mg PO once daily for 10 days) is recommended for adolescents in whom enteric organisms (coliforms) are most likely or in whom gonococcal culture or nucleic acid amplification test is negative.",
"      <br>",
"       &Delta;Significant overlap in clinical fndings and diagnostic studies may occur for testicular torsion, torsed appendage, or acute epididymitis. Exploratory surgery may ultimately be necessary to determine the etiology of&nbsp;scrotal&nbsp;pain.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from:",
"     <br>",
"      Burgher, SW. Acute scrotal pain. Emerg Med Clin North Am 1998; 16:781.",
"      <br>",
"       Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Recomm Rep 2006; 55:1.",
"       <br>",
"        Updated recommended treatment guidelines for gonococcal infections and associated treatment conditions - United States, April 2007. Available at: www.cdc.gov/std/treatment/2006/GonUpdateApril2007.pdf.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25485=[""].join("\n");
var outline_f24_56_25485=null;
var title_f24_56_25486="Components energy expenditure";
var content_f24_56_25486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Components of energy expenditure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The components of energy expenditure are basal metabolic activities (such as heat production for maintenance of body temperature, maintenance of ionic gradients across cells, cardiac and respiratory function), the thermic effect of food (thermogenesis), and physical activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George A Bray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25486=[""].join("\n");
var outline_f24_56_25486=null;
var title_f24_56_25487="Drug interactions with PIs NNRTIs CCR5 antagonists";
var content_f24_56_25487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug interactions with PIs, NNRTIs, and CCR5 antagonists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug category*&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcium channel blockers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardiac agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipid lowering agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        <em>",
"         Anti mycobacterials",
"        </em>",
"        &Delta;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antihistamines&loz;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastrointestinal drugs&loz;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuroleptics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Psychotropics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ergot alkaloids (vasoconstrictors)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Herbs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atazanavir",
"       </td>",
"       <td>",
"        Bepridil",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dihydroergotamine (D.H.E. 45)",
"        </p>",
"        <p>",
"         Ergotamine&yen; (various forms)",
"        </p>",
"        <p>",
"         Ergonovine",
"        </p>",
"        <p>",
"         Methylergonovine",
"        </p>",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <p>",
"         Fluticasone",
"        </p>",
"        <p>",
"         Indinavir",
"        </p>",
"        <p>",
"         Irinotecan",
"        </p>",
"        <p>",
"         Proton pump inhibitor (not recommended for unboosted ATV)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Darunavir/ritonavir",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <p>",
"         Carbamazepine",
"        </p>",
"        <p>",
"         Phenobarbital",
"        </p>",
"        <p>",
"         Phenytoin",
"        </p>",
"        <p>",
"         Fluticasone",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fosamprenavir",
"       </td>",
"       <td>",
"        Bepridil",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <p>",
"         Delavirdine",
"        </p>",
"        <p>",
"         Fluticasone",
"        </p>",
"        <p>",
"         Oral contraceptives",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indinavir",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        Atazanavir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lopinavir/ritonavir",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Flecainide",
"        </p>",
"        <p>",
"         Propafenone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        Fluticasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nelfinavir",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ritonavir",
"       </td>",
"       <td>",
"        Bepridil",
"       </td>",
"       <td>",
"        <p>",
"         Amiodarone",
"        </p>",
"        <p>",
"         Flecainide",
"        </p>",
"        <p>",
"         Propafenone",
"        </p>",
"        <p>",
"         Quinidine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        Rifapentine",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <p>",
"         Voriconazole (with RTV &ge;400 mg BID)",
"        </p>",
"        <p>",
"         Fluticasone",
"        </p>",
"        <p>",
"         Alfuzosin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saquinavir/ritonavir",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        <p>",
"         St. John's wort",
"        </p>",
"        <p>",
"         Garlic supplements",
"        </p>",
"       </td>",
"       <td>",
"        Fluticasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tipranavir/ritonavir",
"       </td>",
"       <td>",
"        Bepridil",
"       </td>",
"       <td>",
"        <p>",
"         Amiodarone",
"        </p>",
"        <p>",
"         Flecainide",
"        </p>",
"        <p>",
"         Propafenone",
"        </p>",
"        <p>",
"         Quinidine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        Pimozide",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        Fluticasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Efavirenz",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        Rifapentine&Delta;",
"       </td>",
"       <td>",
"        <p>",
"         Astemizole",
"        </p>",
"        <p>",
"         Terfenadine",
"        </p>",
"       </td>",
"       <td>",
"        Cisapride",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam&sect;",
"        </p>",
"        <p>",
"         Triazolam",
"        </p>",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etravirine",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine&Delta;",
"        </p>",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        Unboosted PIs, ritonavir-boosted atazanavir, fosamprenavir, or tipranavir, other NNRTIs, carbamazepine, phenobarbital, phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevirapine",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        Rifapentine&Delta;",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rilpivirine&nbsp;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        <p>",
"         Rifabutin",
"        </p>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Rifapentine&Delta;",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;Proton pump inhibitors",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        (None)",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <p>",
"         Carbamazepine",
"        </p>",
"        <p>",
"         Oxcarbazepine",
"        </p>",
"        <p>",
"         Phenobarbital",
"        </p>",
"        <p>",
"         Phenytoin",
"        </p>",
"        <p>",
"         Other NNRTIs",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maraviroc",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Rifapentine&Delta;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Suggested alternatives to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"12\">",
"        <strong>",
"         Lovastatin, simvastatin",
"        </strong>",
"        : Pravastatin and fluvastatin have the least potential for drug-drug interactions (except for pravastatin with darunavir/ritonavir); atorvastatin and rosuvastatin - use with caution, start with the lowest possible dose and titrate based on tolerance and lipid-lowering efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"12\">",
"        <strong>",
"         Rifampin",
"        </strong>",
"        : Rifabutin (with dosage adjustment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"12\">",
"        <strong>",
"         Astemizole, terfenadine (no longer marketed in the United States)",
"        </strong>",
"        : desloratadine, loratadine, fexofenadine, cetirizine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"12\">",
"        <strong>",
"         Midazolam, triazolam",
"        </strong>",
"        : temazepam, lorazepam",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Certain listed drugs are contraindicated based on theoretical considerations. Thus, drugs with narrow therapeutic indices and suspected metabolic involvement with CYP450 3A, 2D6, or unknown pathways are included in this table. Actual interactions may or may not occur among patients.",
"     <br>",
"      &bull; Delavirdine is not included in this table. Refer to the FDA package insert for information regarding delavirdine drug interactions.",
"      <br>",
"       &Delta; HIV patients treated with rifapentine have a higher rate of TB relapse than those treated with other rifamycin-based regimens; an alternative agent is recommended.",
"       <br>",
"        &loz; Astemizole and terfenadine are not marketed in the United States. The manufacturer of cisapride has a limited-access protocol for patients who meet specific clinical eligibility criteria.",
"        <br>",
"         &sect; Contraindicated with oral midazolam. Parenteral midazolam can be used with caution as a single dose and can be given in a monitored situation for procedural sedation.",
"         <br>",
"          &yen; This is likely a class effect.",
"          <br>",
"            Concomitant use of fluticasone and ritonavir results in significantly reduced serum cortisol concentrations. Coadministration of fluticasone and ritonavir or any ritonavir-boosted PI regimen is not recommended unless potential benefit outweighs risk of systemic corticosteroid adverse effects. Fluticasone should be used with caution, and alternatives should be considered, if given with an unboosted PI regimen.",
"           <br>",
"             A high rate of grade 4 serum transaminase elevation was seen when a higher dose of ritonavir was added to lopinavir/ritonavir or saquinavir or when double-dose lopinavir/ritonavir was used with rifampin to compensate for rifampin's induction effect, so these dosing strategies should not be used.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, October 14, 2011. file://www.aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_56_25487=[""].join("\n");
var outline_f24_56_25487=null;
